帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好，仅出现轻度胃肠道不良事件，并展现出有前景的活性，值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发性头颈部鳞状细胞癌肿瘤微环境的变化及其对免疫检查点抑制剂疗效的提示
英文原题：Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors.
查看英文原题
Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发和/或转移性（R/M）头颈部鳞状细胞癌（HNSCC）中TIL（肿瘤浸润淋巴细胞）丰度及免疫表型（IP）的变化尚不清楚。本研究采用配对分析，比较初发与复发HNSCC中的TIL和IP。研究纳入37例患者，他们在手术切除后复发，并于2014年6月至2023年6月期间接受免疫检查点抑制剂（ICI）治疗。对初发和复发肿瘤中的瘤内TIL（iTIL）、间质TIL（sTIL）及IP变化进行了配对分析，并考察其与ICI治疗结局的关系。复发肿瘤中的iTIL和sTIL密度均显著低于初发肿瘤。IP也存在显著差异：复发肿瘤中免疫荒漠型IP比例更高（83.8%对35.1%，P<0.001）。sTIL增加是ICI总体应答和无进展生存期的有利指标。研究结果提示，与初发肿瘤相比，复发过程中TIL减少，肿瘤免疫表型转向免疫荒漠型。因此，对R/M HNSCC患者使用ICI时，建议仔细评估初发及复发肿瘤中的TIL密度。
展开英文摘要原文
Little is known about changes in the abundance of tumor-infiltrating lymphocytes (TILs) and immune phenotype (IP) in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
We aimed to compare the TILs and IP between initial and recurrent HNSCCs using paired analysis. Thirty-seven patients who experienced recurrence after surgical resection and received treatment with immune checkpoint inhibitors (ICIs) between June 2014 and June 2023 were included. Changes in intratumoral TIL (iTILs), stromal TIL (sTILs), and IPs were subjected to paired analysis between the initial and recurrent tumors.
We investigated their relationship with the outcomes of ICIs. The density of iTIL and sTIL in the recurrent tumors was significantly lower compared to initial tumors. IP was significantly different; the proportion of desert IP was higher in recurrent tumors (83. 8% vs. 35. 1%, P < 0. 001). Increased sTIL was a favorable indicator for overall response to ICIs and progression-free survival.
Our findings suggest TILs decrease during recurrence compared with the initial tumor, resulting in a transition toward desert IP.
Therefore, careful evaluation of TIL density in both initial and recurrent tumors is recommended when using ICIs in patients with R/M HNSCC.
论文信息
- 作者
- Kim DH、Kang M、Park G、Mostafavi M、Lim Y、Ock CY、Koh J、Jeon YK
- 第一作者单位
- Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-Ro, Jongro-Gu, Seoul, 03080, Republic of Korea.South Korea
- 通讯作者单位
- Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-Ro, Jongro-Gu, Seoul, 03080, Republic of Korea. bhumsuk@snu.ac.kr.South Korea
- 期刊
- Discover oncology2024 Nov 20
- 原文标识
- PubMed 39567471 · DOI 10.1007/s12672-024-01504-0
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →